Weiwei Tang
Impact in
- Cancer Research top 0.5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 2%
- Circular RNAs in diseases
- RNA modifications and cancer
- Extracellular vesicles in disease
Papers in
-
- Circular RNAs in diseases 24
- RNA modifications and cancer 10
- RNA Research and Splicing 8
- Oncology 35
- Cancer Immunotherapy and Biomarkers 14
- Co-authors
- Dawei Rong (24 shared papers)Xuehao Wang (16 shared papers)Hongyong Cao (24 shared papers)Fan Wu (13 shared papers)Qian Wang (7 shared papers)Handong Sun (7 shared papers)Ye Cheng (14 shared papers)Wenling Zhang (7 shared papers)
In The Last Decade
Weiwei Tang
120 papers receiving 4.2k citations
Weiwei Tang's Hit Papers
Peers
Comparison fields: 5 of 146
- Cancer Research 2.0k
- Molecular Biology 2.7k
- Hepatology 229
- Immunology 574
- Oncology 667
Countries citing papers authored by Weiwei Tang
This map shows the geographic impact of Weiwei Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Tang more than expected).
Fields of papers citing papers by Weiwei Tang
This network shows the impact of papers produced by Weiwei Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Tang. The network helps show where Weiwei Tang may publish in the future.
Co-authors
The 25 scholars most cited alongside Weiwei Tang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 122 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects Hit paper breakdown → | 2020 | 752 |
| 2 | An emerging function of circRNA-miRNAs-mRNA axis in human diseases Hit paper breakdown → | 2017 | 399 |
| 3 | Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing Hit paper breakdown → | 2022 | 194 |
| 4 | 2017 | 132 | |
| 5 | 2021 | 110 | |
| 6 | 2018 | 87 | |
| 7 | Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives Hit paper breakdown → | 2024 | 84 |
| 8 | 2007 | 78 | |
| 9 | 2018 | 78 | |
| 10 | 2021 | 77 | |
| 11 | 2022 | 77 | |
| 12 | 2020 | 77 | |
| 13 | 2022 | 70 | |
| 14 | 2014 | 67 | |
| 15 | 2022 | 66 | |
| 16 | 2021 | 65 | |
| 17 | 2023 | 64 | |
| 18 | 2021 | 64 | |
| 19 | 2022 | 57 | |
| 20 | 2021 | 53 |
About Weiwei Tang
Weiwei Tang is a scholar working on Molecular Biology, Oncology, Cancer Research, Immunology and Pulmonary and Respiratory Medicine, having authored 122 papers that have together received 4.3k indexed citations. Recurring topics across this work include Circular RNAs in diseases (24 papers), MicroRNA in disease regulation (18 papers), Cancer-related molecular mechanisms research (16 papers), Cancer Immunotherapy and Biomarkers (14 papers), RNA modifications and cancer (10 papers), Immune cells in cancer (10 papers), RNA Research and Splicing (8 papers) and Ferroptosis and cancer prognosis (8 papers). The work is most often cited by research in Cancer Research (2.0k citations), Molecular Biology (2.7k citations), Hepatology (229 citations), Immunology (574 citations) and Oncology (667 citations). Weiwei Tang has collaborated with scholars based in China, Germany and Taiwan. Frequent co-authors include Dawei Rong, Xuehao Wang, Hongyong Cao, Fan Wu, Qian Wang, Handong Sun, Ye Cheng, Wenling Zhang, Kai Fu and Zhouxiao Li. Their work appears in journals such as OncoTargets and Therapy, Journal of Oncology, Scientific Reports, Cancer Research and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.